- 4basebio
- 03 May 2024 17:20:50
Source: Sharecast
The AIM-traded firm said the milestone came after the conclusion of an ‘opDNA’ evaluation study.
As a result, the client had advanced to using HQ opDNA for late preclinical studies within an mRNA vaccine program.
4basebio said delivery of GMP-grade material for clinical trials was expected in the third quarter.
“This is a major achievement for our company and is significant both in terms of product quantity and value,” said chief executive officer Dr Heikki Lanckriet.
“It’s a clear recognition of the strengths of our synthetic DNA products, our product quality, and our manufacturing capabilities.”
Dr Lanckriet said there was “strong interest” in the company’s synthetic DNA products, adding that it was now supporting a growing number of projects into the clinic.
“We expect client acquisition and revenue generation to continue accelerating as our expanding client base progress their clinical programmes.”
At 0907 BST, shares in 4basebio were up 4.09% at 968p.
Reporting by Josh White for Sharecast.com.